Meeting
2020 ASCO Virtual Scientific Program
Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.
Authors
R. Brian Mitchell
Virginia Cancer Inst, Midlothian, VA
R. Brian Mitchell , Patricia Rich , Paul R. Walker , Eric S Schaefer , Jiahuai Tan , Nagaprasad Nagajothi , John W. Dubay , Jason Keith Boyd , David N. Oubre , Nadeem Ikhlaque , Ray D. Page , Mazen Khalil , Suman Sinha , Hafez Halawani , S. Scott Boniol , Edgardo S. Santos , James Michael Orsini , Emily K. Pauli , Wallace L. Akerley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9545)
DOI
10.1200/JCO.2020.38.15_suppl.9545
Abstract #
9545
Poster Bd #
311
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
First Author: Lova Sun
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau
Poster
2020 ASCO Virtual Scientific Program
Physiologic colonic uptake of 18F-FDG on PET/CT predicts immunotherapy response and gut microbiome diversity in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Lena Cvetkovic
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki